Avedro, founded in 2009, is a privately held commercial-stage ophthalmic medical technology company focused on treating corneal ectatic disorders and improving vision to reduce dependency on eyeglasses or contact lenses.
Latest Press from Avedro
- Avedro Receives FDA Approval for Photrexa® Viscous, Photrexa® and the KXL® System for Corneal Cross-Linking 04.18.2016
- China Food and Drug Administration (CFDA) Grants Approval for Avedro’s KXL® System 11.03.2015
- Avedro Receives the European Union’s CE Mark for its Vedera™ Ophthalmic Device 04.20.2010